Information Library
Phase I/IIa
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
QUINTILES PARTNERS WITH FOUNDATION TRUST & UNIVERSITY TO IMPROVE PATIENT CARE AND DRIVE EFFICIENCY IN CLINICAL RESEARCH
October 26, 2009 - A significant step in driving innovation, improving patient care and increasing efficiency in early stage clinical research was taken today with the announcement that two of the UK’s leading institutions - Guy’s and St Thomas’ NHS Foundation Trust and King’s College London - have signed a collaborative agreement with Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. -
QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS
September 24, 2009 - Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. Located within the Alba Campus, a research and development center near Edinburgh, the 115,000-square-foot building hosts more than 500 employees and has space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management. -
Changing the Face of Cancer Research
August 31, 2009
Christopher Ung, Vice President, Strategic Business & Operations, Oncology, at TMD, a Quintiles Central Laboratory, explains how advances in biomarker technology are ushering in a new era of cancer therapy development. -
Phase One Services: Professor Anders E. Grahnen
July 24, 2009
With the current high costs of drug development, it's crucial that you can establish the potential success of your agent before the end of Phase II. Our market-leading expertise in biomarkers and specialist techniques can help you do just that. -
Phase One Services: Dr. Brock G. Guernsey
July 24, 2009
Why wait two months to see your data and delay critical decisions when we can deliver your data within a week using electronic bedside data entry? Consider what a 2-month delay means to your drug's development plan? Whether you've done preclinical work and need a rapid Proof of Concept study or are looking for a benchmark of how your drug performs in a specific disease state, we can help. -
Phase One Services: Dr. Elizabeth Allen
July 24, 2009
In 2008 TUFTS reported that it costs over $1 billion to develop a new biopharmaceutical product. Half of this investment occurs in the later stages of testing. Thankfully at Quintiles, we provide accurate and correct Phase I and IIa data quickly. We can help you make smart, safe decisions earlier to avoid repeating costly studies later. -
Phase One Services: Dr. Philip T. Leese
July 24, 2009
At Quintiles, we appreciate the data collection from the clinic as one of the most important parts of a study process. To deliver quality data on time, we ensure that all clinical conduct is consistent, efficient and accurate to your protocol. But to do this we also need to recruit the right volunteers. Our database of clearly defined volunteers means we can quickly call upon participants for student specific screening, saving you time and money. What's more, we also use a range of recruitment methods to keep the database up to date with interested volunteers. -
Phase One Services: Professor Timothy G.K. Mant
July 24, 2009
You can only have total confidence in the integrity and analysis of results of you're sure your study has been conducted in exceptional clinical conditions. So it's absolutely crucial that your Phase I/IIa partner places ethics, safety and expert clinical conduct at the heart of all their activities. -
Validated Biomarker Menu
July 14, 2009
A comprehensive menu of validated cell, fluid and tissue based biomarker assays. -
Multiple Phase I Study for Two Compounds
June 30, 2009
Learn how Quintiles efficiently managed 15 Phase I studies.